Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Look Action for Health in Diabetes (AHEAD) study showed a significant decrease in Michigan Neuropathy Screening Instrument (MNSI)-questionnaire score along with weight loss, but this study did not show a significant difference in MNSI-physical examination [16]
The mechanism behind constipation related to Mounjaro involves the drugs effect on gastric emptying and intestinal motility
Immunol., 16, 1451-1458 9
For BPC-157, this means introducing bacteriostatic water into the sealed vial, allowing the powder to fully dissolve, and producing a stable solution that maintains the peptides structural integrity throughout the research protocol